Ask AI
ProCE Banner Activity

NIAGARA: Exploratory ctDNA Analysis in Patients With MIBC Who Received Neoadjuvant Chemotherapy With or Without Durvalumab

Conference Coverage
Slideset

An exploratory analysis from the randomized phase III NIAGARA trial suggested the prognostic value of ctDNA status in patients with muscle-invasive bladder cancer and confirmed the survival benefits of perioperative durvalumab added to neoadjuvant chemotherapy. 

Released: June 10, 2025

Expiration: December 09, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Astellas.

Astellas